Brainstorm Cell Therapeutics Presents Positive Phase 2 Data of NurOwn in Progressive MS

Brainstorm Cell Therapeutics Presents Positive Phase 2 Data of NurOwn in Progressive MS

Brainstorm Cell Therapeutics reported results from a multicenter, open-label phase 2 trial of NurOwn in progressive multiple sclerosis. Results showed a good safety and tolerability profile, relevant CSF biomarker outcomes, and preliminary evidence of efficacy. The company is delivering the data during an oral presentation at the fully digital 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). 

The trial was designed to evaluate intrathecal administration of NurOwn (autologous MSC-NTF cells) in patients with progressive MS. The study achieved the primary endpoint of safety and tolerability. It demonstrated a reduction of neuroinflammatory biomarkers and an increase in neuroprotective biomarkers in the cerebrospinal fluid (CSF) and consistent improvement across MS functional outcome measures, including measures of walking, upper extremity function, vision, and cognition. 

The study was sponsored by Brainstorm Cell Therapeutics with additional financial support for biomarker analyses from the National Multiple Sclerosis Society Fast-Forward Program. It was conducted at the Cleveland Clinic Mellen Center for MS, Cleveland; the Ic...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee